Literature DB >> 30607316

Molecular docking and ADME properties of bioactive molecules against human acid-beta-glucosidase enzyme, cause of Gaucher's disease.

Vijayakumar Subramaniyan1, Sathiya Mathiyalagan1,2,3, Arulmozhi Praveenkumar1,2,3, Prabhu Srinivasan1, Manogar Palani1, Vinothkannan Ravichandran2, Parameswari Nallasamy3.   

Abstract

Gaucher disease is one of the common lysosomal storage diseases widespread all over the world. It is divided into three types such as type 1 (non-neuropathic), type 2 (acute infantile neuropathic) and type 3 (chronic neuropathic). This is caused by the deficiency of glucocerebrosidases from the midpoint nervous system. Recent years, computational tools are very important and play a vital role in identifying new leads for disease treatment. This study was performed to screen the effective bioactive molecules against glucocerebrosidases. In this study, Molecular docking and ADME profiles of bioactive molecules were found with the help of Schrödinger software. Results showed that, (-)-epicatechin are having best docking score and good binding affinity than other ligands. Hence, we concluded that the (-)-epicatechin may be a better drug candidate for gaucher disease which can be explored further.

Entities:  

Keywords:  ADME profile; Acid β-glucosidase; Bioactive molecules; Molecular docking

Year:  2018        PMID: 30607316      PMCID: PMC6314663          DOI: 10.1007/s40203-018-0039-3

Source DB:  PubMed          Journal:  In Silico Pharmacol        ISSN: 2193-9616


  2 in total

1.  Anti-dengue Potential of Mangiferin: Intricate Network of Dengue to Human Genes.

Authors:  K Kalaimathi; J Maria Jancy Rani; S Vijayakumar; N Prakash; K Karthikeyan; G Thiyagarajan; K Bhavani; S Prabhu; G Varatharaju
Journal:  Rev Bras Farmacogn       Date:  2022-05-07       Impact factor: 2.464

2.  Virtual Screening of Natural Chemical Databases to Search for Potential ACE2 Inhibitors.

Authors:  Huiping Yao
Journal:  Molecules       Date:  2022-03-07       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.